MedTech News
.................... by Andrew Celentano

New drug-delivery method offers promise in fight against neurodegenerative diseases
For patients battling neurodegenerative diseases like ALS, Parkinson’s, Alzheimer’s and other dementias, delivering disease-fighting antibody drugs directly to the brain has proven to be a difficult task. Our bodies set up tight walls to prevent infections from spreading to the brain, where they often become fatal.

Fueling growth, blinding immunity: The two-way amino acid trap inside tumors
Tumors possess myriad mechanisms to ensure their survival even at the peril of the host. Now scientists are delving deeper into how cancer cells alter the metabolism of specific amino acids to support the malignancy’s growth while simultaneously evading the antitumor activity of the host’s immune system.

UCB announces U.S. FDA approval for ZILBRYSQ® (zilucoplan) autoinjector
ATLANTA, Oct. 20, 2026 /PRNewswire/ — UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the first self-administered once-daily autoinjector administration option for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive with ZILBRYSQ® (zilucoplan).¹ The autoinjector is designed to help simplify self-administration of ZILBRYSQ, offering patients another administration option and a more convenient treatment experience.2,3

A Blood Test That Could Detect Breast Cancer as Early as Stage I Has Started Clinical Trials
A new blood test that could lead to earlier detection and treatment of breast cancer.

Study Finds Common Chemicals May Alter Normal Breast Development
Exposure to hormone-disrupting chemicals may leave molecular changes that could someday help identify people at higher risk of breast cancer

AI model decodes the language cells use to communicate
A new computational approach reveals how cells communicate to assemble into tissues. This could accelerate stem cell engineering, improve disease models, and inform therapies.

Centinel Spine gets FDA nod for two-level use of prodisc C Nova
The FDA clearance permits the motion-preserving device to be implanted across two levels in the cervical spine.

How cell type influences the impact of cancer-related protein activity in colorectal cancer
Research has revealed that the role of an important protein in colorectal cancer may vary significantly depending on which cells it is active in. The study, published in the journal npj Precision Oncology, shows that activity of a protein called mTOR may be associated with a stronger immune response in colorectal cancer when it is active in immune cells.